U.S. Physical Therapy reaffirms $102M-$106M adjusted EBITDA guidance as NYU Langone rollout expands into Q3 (NYSE:USPH)

USPH reaffirmed full-year adjusted EBITDA guidance of $102M–$106M despite Q2 operational momentum, signaling management confidence in execution while acknowledging margin headwinds that temper upside expectations. The company achieved record visit volumes and secured reimbursement gains, demonstrating underlying demand strength in outpatient physical therapy services.

The NYU Langone rollout expansion into Q3 represents a material partnership milestone that could drive incremental patient volume and geographic diversification. However, the absence of guidance raise—despite record visits—suggests offsetting cost pressures or pricing environment constraints that limit near-term margin expansion, a critical metric for valuation multiples in this sector.

Management's reaffirmation rather than raise indicates cautious positioning heading into the second half, likely reflecting visibility challenges around labor costs, facility utilization efficiency, and payer mix dynamics in the outpatient rehabilitation space. The data supports stable operational execution but not inflection-level growth acceleration.

Sector implication: Health Care providers face persistent reimbursement pressure despite volume growth, constraining profitability and limiting investor enthusiasm even when topline metrics improve. This pattern reinforces defensive posture in healthcare services during periods of macro uncertainty.